Table 2. Disease characteristics, demographics, clinical characteristics, therapy, and outcomes of 7 solid organ transplant recipients with VL, Madrid, Spain, January 1, 2005–January 1, 2013*.

Characteristics	Patient no.
	1	2	3	4	5	6	7
Sex	M	M	M	M	M	F	M
Race	Black	Black	White	White	White	White	White
Linear distance from patient’s residence to park, m	794	399	261	1,240	985	233	358
Age at transplant, y	35	34	76	55	68	49	52
Type of SOT	Kidney	Kidney	Kidney	Kidney	Kidney	Heart	Kidney
Donor Leishmania spp. serostatus	Negative	NP	Negative	NP	Negative	Negative	Negative
Pretransplant recipient Leishmania spp. serostatus	NP	NP	Negative	Positive	Negative	Negative	Negative
Date of transplant	2011 Feb 11	2010 Jan 22	2010 Mar 10	2010 Jul 7	2009 Dec 29	2010 Sep 5	2010 Apr 15
Interval from transplant to VL diagnosis, y	1.17	2.44	0.25	1.4	0.17	1.81	2.21
Fever at admission	Yes	Yes	No	Yes	Yes	Yes	Yes
Pancytopenia	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Splenomegaly	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Serologic testing results for Leishmania spp.	Positive	Negative	Negative	Positive	Negative	Positive	Negative
Presence of amastigote forms in bone marrow sample	Positive	Positive	Positive	Positive	Positive	Positive	Positive
PCR assay results of bone marrow sample	NP	NP	NP	Negative	NP	NP	NP
NNN culture results of bone marrow sample	Positive	NP	Positive	Negative	Negative	Positive	Negative
Initial therapy	L-AmB	L-AmB	L-AmB	L-AmB	L-AmB	L-AmB	L-AmB
Relapse	Yes	No	Yes	Yes	No	No	No
Outcome	Renal failure	Graft loss	Cured	Graft loss	Cured	Cured	Cured

*L-AmB, liposomal amphotericin B; NNN, Novy-McNeal-Nicolle; NP, not performed; SOT, solid organ transplant; VL, visceral leishmaniasis.